No Data
No Data
Jefferies, BMO Bullish on Newly Public Metagenomi
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Beam Therapeutics: Financial and Clinical Prospects Inform Hold Rating
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating
Beam Therapeutics (BEAM) has an average outperform rating and a price target range of $19 to $78, according to analysts polled by Capital IQ. Price: 44.53, Change: -0.54, Percent Change: -1.20
Beam Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/28/2024 -23.36% RBC Capital $27 → $35 Maintains Sector Perform 01/29/2024 -12.42% JP Morgan $38 → $40 U
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk
Beam Therapeutics (BEAM) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $19 to $78. Price: 45.24, Change: +0.17, Percent Change: +0
No Data